JN

Jack Nielsen

Managing Partner at Vivo Capital

Palo Alto, California

Invests in

Stages:

  • Min Investment:

    $10,000,000.00
  • Max Investment:

    $50,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

  • Managing Partner

    2017

  • Consultant

    2017 - 2017

2021

  • Board Member

    2021

2021

  • Board Member

    2021

    IO Biotech went public on Nasdaq in November 2021 under Ticker IOBT

2020

  • Board Member

    2020

    Instil Bio went public on Nasdaq in March 2021 under Ticker TIL

  • Board Member

    2020

    ALX Oncology went public on Nasdaq in July 2020 under Ticker ALXO

  • Chairman / Lead Director

    2018

    Aligos went public on Nasdaq in October 2020 under Ticker ALGS

  • Board Member

    2017

    Harmony Biosciences went public on NASDAQ August 2020 under ticker HRMY

2006 - 2022

  • Lead Director - Board Member

    2006 - 2022

    Reata went public on Nasdaq in May 2016 under Ticker RETA. Acquired by Biogen in 2023 for $7.3 BUSD

  • Board Member

    2019 - 2022

    LumiThera acquired the Maculogix in 2022

2018 - 2020

  • Board Observer

    2018 - 2020

    Passage Bio raised 216 MUSD in an IPO on NASDAQ under ticker PASG